Pulmonary Arterial Hypertension

Cardiovascular·MeSH: Pulmonary Arterial Hypertension

Prevalence

5.0 / 100K

Incidence

2.4 / 100K/yr

42 drugs in development·27 companies·29 clinical trials

Drug Pipeline by Phase

Approved(13)

Drug	Company
adcirca	ELI LILLY & Co (LLY)
Adcirca	UNITED THERAPEUTICS Corp (UTHR)
ambrisentan	Mylan II B.V. (MYL)
epoprostenol	Mylan II B.V. (MYL)
letairis	GILEAD SCIENCES, INC. (GILD)
macitentan	Mylan II B.V. (MYL)
Orenitram	UNITED THERAPEUTICS Corp (UTHR)
Remodulin	UNITED THERAPEUTICS Corp (UTHR)
revatio	Viatris Inc (VTRS)
treprostinil	Teva Pharmaceutical Industries Limited (TEVA)
tyvaso dpi	MANNKIND CORP (MNKD)
Winrevair	Merck & Co., Inc. (MRK)
YUTREPIA	Liquidia Corp (LQDA)

Phase 3(10)

Drug	Company
ikt-001	Inhibikase Therapeutics, Inc. (IKT)
ikt-001pro	Inhibikase Therapeutics, Inc. (IKT)
Macitentan	Crinetics Pharmaceuticals, Inc. (CRNX)
ralinepag	ARENA PHARMACEUTICALS INC (ARNA)
Selumetinib Oral Capsule	UNITED THERAPEUTICS Corp (UTHR)
seralutinib	XOMA Royalty Corporation (XOMA)
seralutinib	Gossamer Bio, Inc. (GOSS)
seralutinib (GB002)	Gossamer Bio, Inc. (GOSS)
Sotatercept	Merck & Co., Inc. (MRK)
vi-0106	VIVUS INC (VVUS)

Phase 2(6)

Drug	Company
Cabozantinib Oral Tablet	UNITED THERAPEUTICS Corp (UTHR)
cibotercept (KER-012)	Keros Therapeutics, Inc. (KROS)
GB002	Gossamer Bio, Inc. (GOSS)
oral treprostinil	UNITED THERAPEUTICS Corp (UTHR)
regn13335	REGENERON PHARMACEUTICALS, INC. (REGN)
sotatercept	ACCELERON PHARMA INC (XLRN)

Phase 1(2)

Drug	Company
Atovaquone Oral Suspension	UNITED THERAPEUTICS Corp (UTHR)
Treprostinil Palmitil	INSMED Inc (INSM)

Preclinical(5)

BLA Filed(1)

Drug	Company
trevyent	STEADYMED LTD. (STDY)

Phase 1/Phase 2(2)

Drug	Company
ltp	Novartis AG (NVS)
ltp	NOVARTIS AG (NVSEF)

Phase 4(3)

Drug	Company
Initiating daily oral PrEP during pregnancy	UNITED THERAPEUTICS Corp (UTHR)
Parenteral Treprostinil	UNITED THERAPEUTICS Corp (UTHR)
Treprostinil	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 42 drugs in development for Pulmonary Arterial Hypertension across 27 companies.

There are 29 clinical trials targeting Pulmonary Arterial Hypertension tracked by BioSniper.

The estimated prevalence of Pulmonary Arterial Hypertension is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.